A two-year-old CDMO that has created its manufacturing network snapping up unwanted plants is buying a former Hospira sterile plant from Pfizer. …
A global shortage of hepatitis B vaccine has developed as both Merck & Co. and GlaxoSmithKline deal with manufacturing issues.
Pfizer committed to building a $100 million gene therapies plant in North Carolina. The project is expected to create 40 jobs.
A Canadian company that sells topical vitamin C skin treatments is in trouble with the FDA, which says it needs is a dose of cGMP practices.
Merck KGaA’s MilliporeSigma and Baylor College of Medicine joined together to work on vaccines against neglected diseases.
The FDA has again turned down approval of a new eye drug from Valeant because of manufacturing issues at its Bausch + Lomb plant in Tampa, Florida.
The Biocon sterile manufacturing plant that got spanked by European and FDA regulators earlier this year has taken another whipping by the FDA.
Shire has found a buyer for a former Baxter vaccine plant in Europe as it continues its manufacturing consolidation after buying Baxalta.
Bayer, which is struggling with its consumer health biz, has recalled more than a million cartons of its Alka-Seltzer Original.
Teva will lay off 7,000 employees by year's end and close 15 plants in the next two years as it tries to offset a deteriorating generics market.